THERAPY DOSSIER · th-6d4715147427

Vincetoxicum arnottianum aerial part extract, ethyl acetate fraction

Nutraceutical · Vincetoxicum arnottianum aerial-part extract (ethyl-acetate fraction); botanical.

Evidence & regulatory context

Mechanism: Vincetoxicum arnottianum aerial-part extract (ethyl-acetate fraction); botanical.
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31935495 ↗2020Reported benefit

Vincetoxicum arnottianum ameliorate inflammation by suppressing oxidative stress and pro-inflammatory mediators in rat.

RatChemical/toxinSprague-DawleyMale300 mg/kg for the ethyl acetate fraction

Model: Carrageenan, formalin and Freund's complete adjuvant-induced paw oedema and croton oil-induced ear inflammation

The ethyl acetate fraction at 300 mg/kg gave the strongest anti-inflammatory activity, inhibiting oedema by 78.06 +/- 4.6 per cent (carrageenan), 54.71 +/- 0.34 per cent (formalin) and 73.12 +/- 1.9 per cent (croton oil), and restoring raised serum IL-1beta, TNF-alpha, IL-6, IL-17 and nitric oxide…

Extraction: extract · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…